Skip to content
Triangle logo TriangleGet started
← Melanoma

HEALTH PROFESSIONAL · SOURCE READING

Vemurafenib

Source: Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 2, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment Option Overview for Melanoma / Systematic Treatment for Unresectable Stage III, Stage IV, and Recurrent Disease / Signal transduction inhibitors / BRAF inhibitors

Vemurafenib, approved by the FDA in 2011, has improved PFS and OS in patients with unresectable or advanced disease. Vemurafenib is an orally available, small-molecule, selective BRAF V600E kinase inhibitor, and its indication is limited to patients with a demonstrated BRAF V600E pathogenic variant by an FDA-approved test.[15]

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice